CLARITIN-D 24 HOUR Drug Patent Profile

When do Claritin-d 24 Hour patents expire, and what generic alternatives are available?

Claritin-d 24 Hour is a drug marketed by Bayer Healthcare Llc and is included in one NDA.

The generic ingredient in CLARITIN-D 24 HOUR is loratadine; pseudoephedrine sulfate. There are thirty-nine drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the loratadine; pseudoephedrine sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Claritin-d 24 Hour

A generic version of CLARITIN-D 24 HOUR was approved as loratadine; pseudoephedrine sulfate by PERRIGO PHARMA INTL on January 30^th, 2003.

Summary for CLARITIN-D 24 HOUR

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	27
Patent Applications:	40
DailyMed Link:	CLARITIN-D 24 HOUR at DailyMed

Recent Clinical Trials for CLARITIN-D 24 HOUR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Andover Research Eye Institute	Phase 4
Rutgers, The State University of New Jersey	Early Phase 1
National Cancer Institute (NCI)	Early Phase 1

See all CLARITIN-D 24 HOUR clinical trials

Pharmacology for CLARITIN-D 24 HOUR

Drug Class	alpha-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists

US Patents and Regulatory Information for CLARITIN-D 24 HOUR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Healthcare Llc	CLARITIN-D 24 HOUR	loratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	020470-002	Nov 27, 2002		OTC	Yes	Yes

Expired US Patents for CLARITIN-D 24 HOUR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Healthcare Llc	CLARITIN-D 24 HOUR	loratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	020470-002	Nov 27, 2002
Bayer Healthcare Llc	CLARITIN-D 24 HOUR	loratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	020470-002	Nov 27, 2002
Bayer Healthcare Llc	CLARITIN-D 24 HOUR	loratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	020470-002	Nov 27, 2002

International Patents for CLARITIN-D 24 HOUR

See the table below for patents covering CLARITIN-D 24 HOUR around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	638019
Singapore	42947	Stable extended release oral dosage composition
Israel	63122	ANTIHISTAMINIC TRICYCLIC ALKYLCARBAMIC AND SULFAMIC ACID ESTERS,THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
Austria	148114

Supplementary Protection Certificates for CLARITIN-D 24 HOUR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1110543	08C0004	France		PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
0152897	2001C/013	Belgium		PRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115
0152897	C00152897/01	Switzerland		FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
0152897	SPC/GB01/012	United Kingdom		PRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115

Market Dynamics and Financial Trajectory for Claritin-D 24-Hour

Last updated: January 11, 2026

Executive Summary

Claritin-D 24-Hour, a combination antihistamine and decongestant medication, dominates the over-the-counter (OTC) allergy relief segment, with a significant market presence in the United States. This report analyzes the current market landscape, key drivers, competitive positioning, regulatory backdrop, and forecasted financial trajectory. The medication, manufactured by Bayer and historically led by Schering-Plough prior to its acquisition by Merck, has benefited from the rising prevalence of allergic conditions, evolving consumer preferences for OTC solutions, and regulatory considerations concerning pseudoephedrine-containing products.

Introduction

Claritin-D 24-Hour combines loratadine (10 mg) with pseudoephedrine (120 mg), offering dual symptomatic relief for allergic rhinitis and nasal congestion. Its popularity stems from the simple once-daily dosing and efficacy profile, making it a staple in allergy medication portfolios. Given the intense competition from both branded and generic formulations, understanding its market dynamics requires examining consumer behavior, regulatory policies, competitive landscape, and broader industry trends.

---

Market Overview

Parameter	Details
Product Composition	Loratadine 10 mg + Pseudoephedrine 120 mg
Indications	Allergic rhinitis, nasal congestion
Market Segment	OTC allergy and cold relief
Key Players	Bayer (Claritin), Mucinex, Zyrtec, Allegra, generics
Global Reach	Primarily US; limited international distribution
Estimated US Market Value (2022)	$2.3 billion (allergy OTC segment)
Growth Rate (CAGR, 2022-2027)	~4.8%, driven by allergies prevalence and aging demographics

---

Key Market Drivers

1. Rising Prevalence of Allergic Conditions

• Epidemiology: According to the CDC, approximately 19.2 million adults and 7.7 million children in the US suffer from allergic rhinitis (AR).¹
• Demographic Trends: Increased urbanization, pollution, and climate change contribute to rising AR incidences.
• Impact: Higher prevalence escalates demand for OTC antihistamines like Claritin-D.

2. Shift Toward OTC Medications

• Consumer Preference: Increasing preference for self-medication drives OTC segment growth.
• Regulatory Ease: Claritin-D’s pseudoephedrine component transitioned from behind-the-counter to OTC in 2006, expanding consumer access.²

3. Regulatory Policy and Pseudoephedrine Control

• Regulation: Pseudoephedrine sales are controlled via the Combat Methamphetamine Epidemic Act of 2005, requiring purchaser ID and sales limits, impacting supply chain and sales channels.³
• Implications: Despite regulatory hurdles, Claritin-D remains a top OTC choice due to brand loyalty and efficacy.

4. Competitive Landscape and Innovation

• Generic Market Penetration: Generics account for over 85% of OTC allergy products, exerting price pressure.
• Product Differentiation: Limited differentiation among brands but strong brand recognition sustains Claritin-D’s market share.

---

Market Challenges and Constraints

Constraint	Description
Regulatory Limitations	Pseudoephedrine restrictions reduce direct-to-consumer sales
Competition	Generic brands and alternative OTC products (Zyrtec, Allegra)
Consumer Trends	Preference for natural remedies and nasal sprays
Price Sensitivity	Increased due to macroeconomic factors and generic options

---

Competitive Analysis

Competitor	Key Strengths	Market Share (Est.)	Price Positioning	Differentiators
Bayer (Claritin)	Strong brand equity, effective marketing	60% (OTC allergy segment)	Premium	Proven efficacy, consumer trust
Zyrtec (Johnson & Johnson)	Fast onset, potency	20%	Moderate to high	Broad age applicability, OTC availability
Allegra (Sanofi)	Long-lasting, non-drowsy claims	10%	Moderate	Dual mechanism, prescription to OTC shift
Generics	Price competitiveness	10%	Low	Cost-effective options for consumers

---

Regulatory Landscape and Legal Considerations

• FDA Policies: Oversight of pseudoephedrine sales access, requiring logbooks, purchaser ID, and limits.⁴
• Labeling & Claims: Regulatory compliance with OTC labeling guidelines, including indications, warnings, and dosage.
• Legal Risks: Potential restrictions or bans due to abuse concerns, impacting product availability and sales forecasts.

---

Financial Trajectory and Forecasting

Historical Sales Data (Past 5 Years)

Year	Sales (USD Billions)	CAGR	Notes
2018	$2.0	—	Established market presence
2019	$2.1	5%	Slight growth
2020	$2.2	4.8%	COVID-19 pandemic impacts
2021	$2.2	0%	Stabilization
2022	$2.3	4.5%	Recovery and increased allergy incidents

Projected Market Trends (2023-2027)

Year	Estimated Sales (USD Billion)	Growth Rate (CAGR)	Key Assumptions
2023	$2.4	4.3%	Continued prevalence rise; stable competition
2024	$2.5	4.2%	Minor price adjustments; generics' impact
2025	$2.6	4%	Market saturation plateau
2026	$2.7	3.8%	Innovation leads to new formulations remains limited
2027	$2.8	3.7%	Slight market consolidation

Factors Influencing Future Growth

• Public health campaigns promoting allergy awareness.
• Advances in formulation: Potential future formulations integrating non-sedating antihistamines with alternative decongestants.
• Regulatory shifts: Possible easing or tightening of pseudoephedrine sales, influencing distribution.

---

Comparison with Close Market Alternatives

Product	Active Ingredients	Dosing Frequency	Price Range (USD)	Market Share	Notable Features
Claritin-D	Loratadine + Pseudoephedrine	Once daily	$10 - $15 (per pack)	Dominant	Trusted brand; high efficacy
Zyrtec-D	Certizine + Pseudoephedrine	Once daily	$12 - $18	Moderate	Fast onset; similar efficacy
Allegra-D	Fexofenadine + Pseudoephedrine	Once daily	$10 - $16	Moderate	Non-drowsy; longer-lasting effect
Generic	Loratadine + Pseudoephedrine	Once daily	$5 - $8	High	Cost advantage; variable brand trust

FAQs

1. What are the primary factors driving Claritin-D's market dominance?

The combination of established efficacy, significant consumer brand loyalty, regulatory approval for OTC sales, and high prevalence of allergic conditions underpin Claritin-D’s market dominance. Its once-daily dosing and trusted brand reputation give it a competitive edge over other OTC options.

2. How do regulatory policies impact Claritin-D sales?

Restrictions on pseudoephedrine sales, such as ID verification and purchase limits, limit direct consumer access, pushing sales through licensed channels. This regulation dampens rapid stock turnover but helps maintain product integrity and control misuse. Future regulatory adjustments may either facilitate or hinder sales growth.

3. What are the main challenges Claritin-D faces from generic competitors?

Generics offer similar efficacy at lower prices, pressuring margin and market share. However, brand recognition and perceived quality temporarily insulate Claritin-D from significant erosion, especially among long-term users.

4. How might evolving consumer preferences affect Claritin-D's trajectory?

There's a growing trend toward natural remedies and non-chemical alternatives. Additionally, consumers favoring nasal sprays or natural antihistamines could displace traditional oral medications, exerting downward pressure on sales.

5. What is the outlook for Claritin-D's financial performance over the next five years?

Forecasts indicate a steady CAGR of approximately 3.7-4.3%, driven by increasing allergy prevalence and stable consumer demand. However, intense competition and regulatory factors pose risks to sustained growth.

---

Key Takeaways

• Market Position: Claritin-D retains a strong market position due to brand trust, efficacy, and consumer familiarity.
• Growth Drivers: Rising allergy prevalence and OTC accessibility underpin future growth, albeit at moderate rates (~3.7-4.3% CAGR).
• Competitive Risks: Price competition from generics and consumer shift toward natural remedies may erode market share.
• Regulatory Impact: Pseudoephedrine controls significantly influence sales channels and volume; future policy shifts could alter trajectory.
• Innovation & Differentiation: Limited ongoing innovation indicates market stability but also risk of obsolescence if newer formulations emerge.

---

References

1. Centers for Disease Control and Prevention (CDC). "Allergic Rhinitis Data," 2021.
2. U.S. Food and Drug Administration (FDA). "OTC Pseudoephedrine Regulations," 2006.
3. Combat Methamphetamine Epidemic Act of 2005, Public Law No: 109-177.
4. FDA. "Labeling and Marketing Policies for OTC Medications," 2020.
5. IQVIA. "OTC Allergy Market Report," 2022.

---

Note: The financial projections and figures are estimates based on current market data and industry trends; actual performance may vary depending on regulatory, economic, and competitive factors.